Neoplasm Metastasis  >>  erlotinib  >>  Phase 2
Welcome,         Profile    Billing    Logout  

11 Trials

Remove FilterRemove FilterRemove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
erlotinib / Generic mfg.
NCT00193622: Bevacizumab and Erlotinib in the Treatment of Patients With Carcinoma of Unknown Primary Site

Completed
2
50
US
Bevacizumab, Erlotinib
SCRI Development Innovations, LLC, Genentech, Inc.
Neoplasms, Unknown Primary
09/05
01/09
NCT00123851: Tarceva, Capecitabine and Oxaliplatin for Metastatic Colorectal Cancer

Completed
2
32
US
Tarceva (OSI-774), Capecitabine, Oxaliplatin
Dana-Farber Cancer Institute, Sanofi-Synthelabo, OSI Pharmaceuticals, Hoffmann-La Roche, Genentech, Inc., Massachusetts General Hospital, Beth Israel Deaconess Medical Center
Colorectal Cancer, Neoplasm Metastasis
08/06
08/06
NCT00116506: Study of Bevacizumab, Erlotinib, FOLFOX for Patients With Untreated Metastatic Colorectal Cancer

Completed
2
35
US
erlotinib, FOLFOX, bevacizumab
Dana-Farber Cancer Institute, Brigham and Women's Hospital, Massachusetts General Hospital, Beth Israel Deaconess Medical Center, Genentech, Inc., Sanofi-Synthelabo
Colorectal Cancer, Neoplasm Metastasis
07/07
07/07
NCT00385398: QOL-Stereotactic RadioSurgery, Temozolomide + Erlotinib-Rx of 1-3 Brain Metastases in NSCLC

Withdrawn
2
0
US
erlotinib hydrochloride, temozolomide, stereotactic radiosurgery
University of Medicine and Dentistry of New Jersey, National Cancer Institute (NCI), Schering-Plough, Genentech, Inc.
Lung Cancer, Metastatic Cancer
12/08
12/08
NCT00461708 / 2006-001518-34: A Study of Tarceva (Erlotinib) in Combination With Gemcitabine in Unresectable and/or Metastatic Cancer of the Pancreas: Relationship Between Skin Toxicity and Survival

Checkmark Data
Dec 2011 - Dec 2011: Data
Completed
2
153
Europe
Erlotinib, Tarceva, Gemcitabine
Hoffmann-La Roche
Pancreatic Cancer
11/10
11/10
TACTIC, NCT00554775 / 2006-000113-38: WBRT & Erlotinib in Advanced NSCLC and Brain Metastases

Checkmark WCLC 2013
Oct 2013 - Oct 2013: WCLC 2013
Terminated
2
80
Europe
erlotinib hydrochloride, tarceva, OSI-774, placebo
University College, London, Cancer Research UK, Roche Pharma AG
Lung Cancer, Metastatic Cancer
11/10
11/10
NCT00800202 / 2008-006504-33: A Study of Avastin (Bevacizumab) in Patients With Non-Squamous Non-Small Cell Lung Cancer With Asymptomatic Untreated Brain Metastasis

Checkmark ASCO 2013
May 2013 - May 2013: ASCO 2013
Checkmark P2 data-ESMO
Sep 2012 - Sep 2012: P2 data-ESMO
Completed
2
91
Europe
bevacizumab [Avastin], carboplatin, erlotinib [Tarceva], paclitaxel
Hoffmann-La Roche
Non-Small Cell Lung Cancer
10/12
10/12
NCT00737243: Treatment Based on Molecular Profiling Diagnosis Carcinoma of Unknown Primary Site

Completed
2
289
US
Paclitaxel, Carboplatin, Bevacizumab, Avastin, Erlotinib, Tarceva, Treatment determined by physician
SCRI Development Innovations, LLC, Genentech, Inc.
Carcinoma
11/12
12/12
NCT01703910 / 2012-001307-20: Study of Individualized Therapies Selection for Patients With Metastatic Colorectal Carcinoma According to the Therapeutic

Completed
2
29
Europe
Arm A chemotherapy, Capecitabine, Cisplatin, Cetuximab, Doxorubicin, Fluorouracil, Gemcitabine, Irinotecan, Topotecan, Mitomycin C, Oxaliplatin, Paclitaxel, Docetaxel, Pemetrexed, Raltitrexed, Sorafenib, Erlotinib, Vinorelbine, Dasatinib, Etoposide, arm B chemotherapy
Centro Nacional de Investigaciones Oncologicas CARLOS III, Hospital Universitario de Fuenlabrada, Grupo Hospital de Madrid, Apices Soluciones S.L.
Adenocarcinoma of Colon, Adenocarcinoma of Rectum, Metastatic Disease
11/12
12/14
LUTRAERL, NCT00473083: Systemic and Topical Treatments for Rash Secondary to Erlotinib in Lung Cancer

Completed
2
150
Canada
Minocycline, Dynacin, Minocin, Minocin PAC, Solodyn, Vectrin, Myrac, Clindamycin 2% in hydrocortisone 1% lotion, Erlotinib, Tarceva, Topical clindamycin 2%, triamcinolone acetonide 0.1% soln
British Columbia Cancer Agency, Hoffmann-La Roche
Rash
12/12
08/13
NCT00997334: Erlotinib Therapy and Subsequent Development of Mechanisms of Secondary Resistance in Patients With NSCLC

Checkmark ASCO 2015
May 2015 - May 2015: ASCO 2015
Completed
2
60
US
Erlotinib, Tarceva
David M. Jackman, MD, Beth Israel Deaconess Medical Center, Brigham and Women's Hospital, Genentech, Inc.
Non-small Cell Lung Cancer
05/15
01/17

Download Options